CNBX Pharmaceuticals Inc. (CNBX)
USD 0.01
(5.93%)
USD 0.01
(5.93%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.21 Million USD | -26.04% |
| 2022 | 1.64 Million USD | 418.94% |
| 2021 | -514.57 Thousand USD | 33.83% |
| 2020 | -777.61 Thousand USD | -192.35% |
| 2019 | -265.98 Thousand USD | 80.91% |
| 2018 | -1.39 Million USD | 58.62% |
| 2017 | -3.36 Million USD | -17507.02% |
| 2016 | -19.12 Thousand USD | 24.19% |
| 2015 | -25.22 Thousand USD | 74.46% |
| 2014 | -98.76 Thousand USD | -462.52% |
| 2013 | 27.24 Thousand USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 100.0% |
| 2009 | -177.74 Thousand USD | 39.04% |
| 2008 | -291.56 Thousand USD | 2.85% |
| 2007 | -300.12 Thousand USD | -126.26% |
| 2006 | -132.64 Thousand USD | -1193.0% |
| 2005 | 12.13 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 1.22 Million USD | -2.79% |
| 2024 Q1 | 1.23 Million USD | 1.53% |
| 2024 Q2 | 1.25 Million USD | 1.86% |
| 2023 Q3 | 1.28 Million USD | -13.62% |
| 2023 Q1 | 1.74 Million USD | 6.12% |
| 2023 Q4 | 1.21 Million USD | -5.79% |
| 2023 FY | 1.21 Million USD | -26.04% |
| 2023 Q2 | 1.49 Million USD | -14.35% |
| 2022 Q1 | 282.25 Thousand USD | 154.85% |
| 2022 FY | 1.64 Million USD | 418.94% |
| 2022 Q2 | 1.09 Million USD | 287.37% |
| 2022 Q3 | 1.5 Million USD | 37.99% |
| 2022 Q4 | 1.64 Million USD | 8.78% |
| 2021 Q4 | -514.57 Thousand USD | 43.77% |
| 2021 Q2 | -566.98 Thousand USD | -208.09% |
| 2021 Q1 | -184.03 Thousand USD | 76.33% |
| 2021 FY | -514.57 Thousand USD | 33.83% |
| 2021 Q3 | -915.07 Thousand USD | -61.39% |
| 2020 Q2 | -586.97 Thousand USD | -83.81% |
| 2020 Q1 | -319.34 Thousand USD | -20.06% |
| 2020 Q3 | -357.62 Thousand USD | 39.07% |
| 2020 Q4 | -777.61 Thousand USD | -117.44% |
| 2020 FY | -777.61 Thousand USD | -192.35% |
| 2019 Q4 | -265.98 Thousand USD | 46.1% |
| 2019 Q1 | -6.57 Million USD | -372.15% |
| 2019 Q2 | -5.16 Million USD | 21.46% |
| 2019 FY | -265.98 Thousand USD | 80.91% |
| 2019 Q3 | -493.5 Thousand USD | 90.45% |
| 2018 Q2 | -2.86 Million USD | 0.83% |
| 2018 Q4 | -1.39 Million USD | 37.09% |
| 2018 FY | -1.39 Million USD | 58.62% |
| 2018 Q1 | -2.88 Million USD | 14.24% |
| 2018 Q3 | -2.21 Million USD | 22.65% |
| 2017 Q4 | -3.36 Million USD | -5.56% |
| 2017 Q3 | -3.19 Million USD | -462.45% |
| 2017 Q2 | -567.21 Thousand USD | -103.92% |
| 2017 Q1 | -278.15 Thousand USD | -1354.23% |
| 2017 FY | -3.36 Million USD | -17507.02% |
| 2016 Q3 | -88.5 Thousand USD | -40.38% |
| 2016 FY | -19.12 Thousand USD | 24.19% |
| 2016 Q4 | -19.12 Thousand USD | 78.39% |
| 2016 Q1 | 10.27 Thousand USD | 140.72% |
| 2016 Q2 | -63.04 Thousand USD | -713.77% |
| 2015 Q3 | -21.55 Thousand USD | -162.46% |
| 2015 FY | -25.22 Thousand USD | 74.46% |
| 2015 Q1 | -65.61 Thousand USD | 33.56% |
| 2015 Q2 | -8211.00 USD | 87.49% |
| 2015 Q4 | -25.22 Thousand USD | -17.07% |
| 2014 Q3 | - USD | 100.0% |
| 2014 FY | -98.76 Thousand USD | -462.52% |
| 2014 Q4 | -98.76 Thousand USD | 0.0% |
| 2014 Q1 | -31.35 Thousand USD | -215.08% |
| 2014 Q2 | -1076.00 USD | 96.57% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 FY | 27.24 Thousand USD | 0.0% |
| 2013 Q4 | 27.24 Thousand USD | 194707.14% |
| 2013 Q3 | -14.00 USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2010 FY | - USD | 100.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q2 | - USD | 100.0% |
| 2010 Q1 | -20.00 USD | 99.99% |
| 2009 Q1 | -290.33 Thousand USD | 0.42% |
| 2009 FY | -177.74 Thousand USD | 39.04% |
| 2009 Q4 | -177.74 Thousand USD | 37.37% |
| 2009 Q3 | -283.77 Thousand USD | 0.46% |
| 2009 Q2 | -285.07 Thousand USD | 1.81% |
| 2008 Q4 | -291.56 Thousand USD | 0.02% |
| 2008 Q3 | -291.61 Thousand USD | 0.36% |
| 2008 Q2 | -292.68 Thousand USD | 2.41% |
| 2008 Q1 | -299.91 Thousand USD | 0.07% |
| 2008 FY | -291.56 Thousand USD | 2.85% |
| 2007 Q1 | -121.75 Thousand USD | 8.22% |
| 2007 Q2 | -309.35 Thousand USD | -154.09% |
| 2007 FY | -300.12 Thousand USD | -126.26% |
| 2007 Q3 | -305.76 Thousand USD | 1.16% |
| 2007 Q4 | -300.12 Thousand USD | 1.85% |
| 2006 Q1 | 13.45 Thousand USD | 0.0% |
| 2006 Q4 | -132.64 Thousand USD | -678.18% |
| 2006 Q3 | 22.94 Thousand USD | 0.0% |
| 2006 Q2 | 22.94 Thousand USD | 70.48% |
| 2006 FY | -132.64 Thousand USD | -1193.0% |
| 2005 FY | 12.13 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 92763.206% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 78.509% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 97.163% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 586.294% |
| Rebus Holdings, Inc. | 305 Thousand USD | -297.996% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 119.254% |
| Qrons Inc. | 351.42 Thousand USD | -245.417% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -95.045% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 97.205% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 6048.099% |
| Skye Bioscience, Inc. | -5.72 Million USD | 121.217% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 92.299% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 70.523% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -202.076% |
| SQZ Biotechnologies Company | -36.23 Million USD | 103.35% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 45.863% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -30.922% |
| Mesoblast Limited | 55.85 Million USD | 97.827% |
| Marizyme, Inc. | 18.56 Million USD | 93.463% |
| Genus plc | 190.6 Million USD | 99.363% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 45.708% |
| Pharming Group N.V. | 109.8 Million USD | 98.894% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -41.11% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -78.513% |
| ContraFect Corporation | -6.02 Million USD | 120.144% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -801.587% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -5.06% |
| IMV Inc. | 7.67 Million USD | 84.175% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 77.937% |
| MultiCell Technologies, Inc. | 90.04 USD | -1348065.26% |
| ONE Bio Corp. | 9.04 Million USD | 86.572% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 265.385% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 90.623% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 11.264% |
| Q BioMed Inc. | 4.06 Million USD | 70.101% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 96.027% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -20.459% |
| Biomind Labs Inc. | 711.4 Thousand USD | -70.633% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 97.995% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 39.287% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 90.521% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -237.463% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -768.278% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -6010.072% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 44.873% |
| GB Sciences, Inc. | 1.74 Million USD | 30.528% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 760.483% |
| HST Global, Inc. | 96.79 Thousand USD | -1154.107% |
| CSL Limited | 10.52 Billion USD | 99.988% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -488.646% |
| Halberd Corporation | 144.72 Thousand USD | -738.778% |
| Enzolytics Inc. | 981.65 Thousand USD | -23.657% |
| Agentix Corp. | 37.63 Thousand USD | -3125.766% |
| Resverlogix Corp. | 6.45 Million USD | 81.183% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 280.346% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.06% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 102.582% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 82.833% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 55.184% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 113.732% |
| AVAX Technologies, Inc. | -5.9 Million USD | 120.563% |
| Zenith Capital Corp. | 10.06 Thousand USD | -11961.685% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.114% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -505.636% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 49.125% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -637.885% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 6726.75% |
| Kadimastem Ltd | -253.1 Thousand USD | 579.604% |
| Helix BioMedix, Inc. | -2.57 Million USD | 147.232% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 94.013% |
| BioStem Technologies, Inc. | 4.47 Million USD | 72.856% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -503.162% |
| LadRx Corporation | -2.03 Million USD | 159.607% |
| Cell Source, Inc. | 9.23 Million USD | 86.851% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -91.113% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -91.113% |
| NovAccess Global Inc. | 2.17 Million USD | 44.278% |
| Affymax, Inc. | -5.59 Million USD | 121.688% |
| Itoco Inc. | 228.3 Thousand USD | -431.696% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -792.637% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 75.512% |
| Mobile Lads Corp. | 484.23 Thousand USD | -150.683% |
| CytoDyn Inc. | 20.26 Million USD | 94.009% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 187717.929% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 13197.146% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 84.247% |
| SYBLEU INC | 473.71 Thousand USD | -156.249% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 72.765% |
| International Stem Cell Corporation | 2.59 Million USD | 53.132% |
| Bioxytran, Inc. | 1.89 Million USD | 36.075% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -1844.928% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 44.34% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 64.651% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 85.807% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -57.116% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 197.111% |
| Neutra Corp. | 52.18 Thousand USD | -2226.035% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 148.77% |
| PureTech Health plc | -167.19 Million USD | 100.726% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 595.651% |
| IXICO plc | -4.44 Million USD | 127.312% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 90.817% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 97.787% |
| CSL Limited | 10.52 Billion USD | 99.988% |
| Cellectis S.A. | -43.81 Million USD | 102.77% |